MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
Balance Sheet
Inspect the capital base behind the business.
Assets
$385.14M
FY 2025 · Annual
+43.4% YoYLiabilities
$15.92M
FY 2025 · Annual
+43.5% YoYEquity
$369.22M
FY 2025 · Annual
+43.4% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $161.7M |
| Short-term Investments | $319.9M |
| Receivables | $3.2M |
| Other Current | $7.9M |
| Total Current Assets | $492.8M |
| PP&E (Net) | $7.6M |
| Other Non-current | $247.0K |
| Total Non-current Assets | $7.9M |
| Total Assets | $500.6M |
Analysis
Selected assets total $500.6M for Latest. The largest visible component is Short-term Investments at $319.9M, about 63.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-8 | S-8 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
How much cash does MBX have?
MBX Biosciences, Inc. Common Stock (MBX) reported $75.29M in cash and equivalents in fiscal 2025.
How much debt does MBX carry?
MBX Biosciences, Inc. Common Stock (MBX) reported $596,000.00 of total debt, with net debt of -$74.69M.
Continue the stock analysis
Jump to another research area for this company.